Base de dados : MEDLINE
Pesquisa : D02.065.589.099.750.750.050.050 [Categoria DeCS]
Referências encontradas : 8736 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 874 ir para página                         

  1 / 8736 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29202138
[Au] Autor:Olajuyigbe OO; Coopoosamy RM; Afolayan AJ
[Ad] Endereço:Department of Nature Conservation, Mangosuthu University of Technology, Durban, KwaZulu-Natal, South Africa.
[Ti] Título:Effects and time-kill assessment of amoxicillin used in combination with chloramphenicol against bacteria of clinical importance.
[So] Source:Acta Biochim Pol;64(4):609-613, 2017.
[Is] ISSN:1734-154X
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:With the emergence of multidrug-resistant organisms in an era when drug development faces challenges causing pharmaceutical companies to curtail or abandon research on anti-infective agents, the use of combined existing antimicrobial agents may be an alternative. This study evaluated the effects of combining amoxicillin and chloramphenicol, to which many bacteria have become resistant, in vitro against Gram positive and Gram negative bacteria by agar diffusion, checkerboard and time-kill assays. The test isolates were susceptible to amoxicillin with minimum inhibitory concentrations (MICs) ranging between 0.448 and 500 µg/ml and between 1.953 and 31.25 µg/ml for chloramphenicol. Upon combining these agents, there was a drastic reduction in their MICs indicating an increased antibacterial activity that showed synergistic interaction against all the bacteria. At the highest concentrations, the inhibition zones ranges were 20.33-38.33±0.58 µg/ml for amoxicillin, 27.67-37.67±0.58 µg/ml for chloramphenicol and 31.67-39.33±0.58 µg/ml for the combined agents. The fractional inhibitory concentration indices (FICIs) showed synergy ranging from 0.129 to 0.312 while FICIs for additive interaction were between 0.688 and 1.0. There was no antagonistic interaction. At the / MICs of the combined antibiotics, all the tested bacteria, except for Klebsiella pneumoniae ATCC 4352, Proteus vulgaris CSIR 0030 and Enterococcus cloacae ATCC 13047 were eliminated before 24 h. At the MICs, all the tested bacteria were eliminated except Enterococcus cloacae ATCC 13047 which was almost totally eliminated. Post-antibiotic assessment after 48 h showed that all the cultures were sterile except for that of Enterococcus cloacae ATCC 13047. The lack of antagonism between these antibacterial agents in checkerboard and time-kill assays suggested that combining amoxicillin with chloramphenicol can provide an improved therapy in comparison to the use of each antibiotic individually. The study indicates the potential beneficial value of combining amoxicillin and chloramphenicol in the treatment of microbial infections in clinical settings.
[Mh] Termos MeSH primário: Amoxicilina/farmacologia
Antibacterianos/farmacologia
Bactérias/efeitos dos fármacos
Cloranfenicol/farmacologia
[Mh] Termos MeSH secundário: Bactérias/isolamento & purificação
Farmacorresistência Bacteriana/efeitos dos fármacos
Sinergismo Farmacológico
Testes de Sensibilidade Microbiana
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 66974FR9Q1 (Chloramphenicol); 804826J2HU (Amoxicillin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.18388/abp.2016_1495


  2 / 8736 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328644
[Au] Autor:Grgov S; Tasic T; Radovanovic-Dinic B; Benedeto-Stojanov D
[Ti] Título:Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
[So] Source:Vojnosanit Pregl;73(11):1044-9, 2016 Nov.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Background/Aim: Some studies suggest the benefit of applying different probiotic strains in combination with antibiotics in the eradication of Helicobacter pylori (H. pylori) infection. The aim of this study was to evaluate the effect of co-administration of multiple probiotic strains with triple H. pylori eradication therapy.This prospective study included 167 patients with dyspeptic symptoms and chronic gastritis who were diagnosed with H. pylori infection and randomized into two groups. The group I of 77 patients underwent triple eradication therapy, for 7 days, with lansoprazole, 2 × 30 mg half an hour before the meal, amoxicillin 2 × 1.000 mg per 12 hours and clarithromycin 2 × 500 mg per 12 hours. After the 7th day of the therapy, lansoprazole continued at a dose of 30 mg for half an hour before breakfast for 4 weeks. The group II of 90 patients received the same treatment as the patients of the group I, with the addition of the probiotic cultures in the form of a capsule comprising Lactobacillus Rosell-52, Lactobacillus Rosell-11, Bifidobacterium Rosell-1755 and Saccharomyces boulardii, since the beginning of eradication for 4 weeks. Eradication of H. pylori infection control was performed 8 weeks after the therapy by rapid urease test and histopathologic evaluation of endoscopic biopsies or by stool antigen test for H. pylori.Eradication of H. pylori infection was achieved in 93.3% of the patients who received probiotics with eradication therapy and in 81.8% of patients who were only on eradication therapy without probiotics. The difference in eradication success was statistically significant, (p < 0.05). The incidence of adverse effects of eradication therapy was higher in the group of patients who were not on probiotic (28.6%) than in the group that received probiotic (17.7%), but the difference was not statistically significant.Multiple probiotic strains addition to triple eradication therapy of H. pylori achieves a significantly better eradication success, with fewer side effects of antibiotics.
[Mh] Termos MeSH primário: Amoxicilina/uso terapêutico
Antibacterianos/uso terapêutico
Claritromicina/uso terapêutico
Gastrite/tratamento farmacológico
Infecções por Helicobacter/tratamento farmacológico
Helicobacter pylori/efeitos dos fármacos
Lansoprazol/uso terapêutico
Probióticos/uso terapêutico
Inibidores da Bomba de Prótons/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Amoxicilina/efeitos adversos
Antibacterianos/efeitos adversos
Biópsia
Doença Crônica
Claritromicina/efeitos adversos
Quimioterapia Combinada
Feminino
Gastrite/diagnóstico
Gastrite/microbiologia
Gastroscopia
Infecções por Helicobacter/diagnóstico
Infecções por Helicobacter/microbiologia
Helicobacter pylori/patogenicidade
Seres Humanos
Lansoprazol/efeitos adversos
Masculino
Meia-Idade
Probióticos/efeitos adversos
Estudos Prospectivos
Inibidores da Bomba de Prótons/efeitos adversos
Sérvia
Fatores de Tempo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); 804826J2HU (Amoxicillin); H1250JIK0A (Clarithromycin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150415127G


  3 / 8736 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29190037
[Au] Autor:Bonet M; Ota E; Chibueze CE; Oladapo OT
[Ad] Endereço:UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research, World Health Organization, Avenue Appia 20, Geneva, Switzerland, CH-1211.
[Ti] Título:Routine antibiotic prophylaxis after normal vaginal birth for reducing maternal infectious morbidity.
[So] Source:Cochrane Database Syst Rev;11:CD012137, 2017 11 13.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Infectious morbidities contribute to considerable maternal and perinatal morbidity and mortality, including women at no apparent increased risk of infection. To reduce the incidence of infections, antibiotics are often administered to women after uncomplicated childbirth, particularly in settings where women are at higher risk of puerperal infectious morbidities. OBJECTIVES: To assess whether routine administration of prophylactic antibiotics to women after normal (uncomplicated) vaginal birth, compared with placebo or no antibiotic prophylaxis, reduces postpartum maternal infectious morbidities and improves outcomes. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 August 2017), LILACS, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (22 August 2017) and reference lists of retrieved studies. SELECTION CRITERIA: We planned to include randomised or quasi-randomised trials evaluating the use of prophylactic antibiotics versus placebo or no antibiotic prophylaxis. Trials using a cluster-randomised design would have been eligible for inclusion, but we found none.In future updates of this review, we will include studies published in abstract form only, provided sufficient information is available to assess risks of bias. We will consider excluded abstracts for inclusion once the full publication is available, or the authors provide more information.Trials using a cross-over design are not eligible for inclusion in this review. DATA COLLECTION AND ANALYSIS: Two review authors conducted independent assessment of trials for inclusion and risks of bias. They independently extracted data and checked them for accuracy, resolving differences in assessments by discussion. They evaluated methodological quality using standard Cochrane criteria and the GRADE approach.We present the summaries as risk ratios (RRs) and mean difference (MDs) using fixed- or random-effect models. For one primary outcome we found considerable heterogeneity and interaction. We explored further using subgroup analysis to investigate the effects of the randomisation unit. All review authors discussed and interpreted the results. MAIN RESULTS: One randomised controlled trial (RCT) and two quasi-RCTs contributed data on 1779 women who had uncomplicated vaginal births, comparing different antibiotic regimens with placebo or no treatment. The included trials took place in the 1960s (one trial) and 1990s (two trials). The trials were conducted in France, the USA and Brazil. Antibiotics administered included: oral sulphamethoxypyridazine or chloramphenicol for three to five days, and intravenous amoxicillin and clavulanic acid in a single dose one hour after birth. We rated most of the domains for risk of bias as high risk, with the exception of reporting bias and other potential bias.The quality of evidence ranged from low to very low, based on the GRADE quality assessment, given very serious design limitations of the included studies, few events and wide confidence intervals (CIs) of effect estimates.We found a decrease in the risk of endometritis (RR 0.28, 95% CI 0.09 to 0.83, two trials, 1364 women,very low quality). However, one trial reported zero events for this outcome and we rate the evidence as very low quality. There was little or no difference between groups for the risk of urinary tract infection (RR 0.25, 95% CI 0.05 to 1.19, two trials, 1706 women,low quality), wound infection after episiotomy (reported as wound dehiscence in the included trials) (RR 0.78, 95% CI 0.31 to 1.96, two trials, 1364 women, very low quality) and length of maternal hospital stay in days (MD -0.15, 95% CI -0.31 to 0.01, one trial, 1291 women, very low quality). Cost of care in US dollar equivalent was 2½ times higher in the control group compared to the group receiving antibiotics prophylaxis (USD 3600: USD 9000, one trial, 1291 women). There were few or no differences between treated and control groups for adverse effects of antibiotics (skin rash) reported in one woman in each of the two trials (RR 3.03, 95% CI 0.32 to 28.95, two trials, 1706 women, very low quality). The incidence of severe maternal infectious morbidity, antimicrobial resistance or women's satisfaction with care were not addressed by any of the included studies. AUTHORS' CONCLUSIONS: Routine administration of antibiotics may reduce the risk of endometritis after uncomplicated vaginal birth. The small number and nature of the trials limit the interpretation of the evidence for application in practice, particularly in settings where women may be at higher risk of developing endometritis. The use of antibiotics did not reduce the incidence of urinary tract infections, wound infection or the length of maternal hospital stay. Antibiotics are not a substitute for infection prevention and control measures around the time of childbirth and the postpartum period. The decision to routinely administer prophylactic antibiotics after normal vaginal births needs to be balanced by patient features, childbirth setting and provider experience, including considerations of the contribution of indiscriminate use of antibiotics to raising antimicrobial resistance. Well-designed and high-powered randomised controlled trials would help to evaluate the added value of routine antibiotic administration as a measure to prevent maternal infections after normal vaginal delivery.
[Mh] Termos MeSH primário: Antibioticoprofilaxia
Parto Obstétrico
Endometrite/prevenção & controle
Infecção Puerperal/prevenção & controle
[Mh] Termos MeSH secundário: Amoxicilina/administração & dosagem
Antibacterianos/administração & dosagem
Cloranfenicol/administração & dosagem
Ácido Clavulânico/administração & dosagem
Endometrite/epidemiologia
Episiotomia/efeitos adversos
Feminino
Seres Humanos
Ensaios Clínicos Controlados não Aleatórios como Assunto
Gravidez
Infecção Puerperal/epidemiologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Sulfametoxipiridazina/administração & dosagem
Infecção da Ferida Cirúrgica/epidemiologia
Infecção da Ferida Cirúrgica/prevenção & controle
Infecções Urinárias/epidemiologia
Infecções Urinárias/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 23521W1S24 (Clavulanic Acid); 66974FR9Q1 (Chloramphenicol); 804826J2HU (Amoxicillin); T034E4NS2Z (Sulfamethoxypyridazine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD012137.pub2


  4 / 8736 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29258111
[Au] Autor:Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
[Ad] Endereço:Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
[Ti] Título:Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
[So] Source:Oncology;93 Suppl 1:15-19, 2017.
[Is] ISSN:1423-0232
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Clarithromycin (CAM)-based triple therapy comprising proton pump inhibitors and amoxicillin is administered as first-line eradication treatment against Helicobacter pylori infection. However, the eradication rate achieved with CAM-based triple therapy has decreased to <80% owing to the emergence of CAM-resistant strains. This prospective randomized study aimed to compare the efficacy of CAM-based and metronidazole (MNZ)-based triple therapy in terms of H. pylori eradication. METHODS: H. pylori-positive patients were treated with CAM-based triple therapy comprising esomeprazole and amoxicillin (EAC group) or with MNZ-based triple therapy comprising esomeprazole and amoxicillin (EAM group). RESULTS: H. pylori eradication rates achieved in the intention-to-treat (ITT) and per protocol (PP) analyses were 70.6 and 72.7%, respectively, in the EAC group. Eradication rates obtained via ITT and PP analyses were 91.7 and 94.3%, respectively, in the EAM group. In the EAC group, eradication rates were significantly lower in patients harboring CAM-resistant strains than in those harboring CAM-sensitive strains. In contrast, eradication rates were comparable between patients harboring CAM-resistant strains and those harboring CAM-sensitive strains in the EAM group. CONCLUSION: MNZ-based triple therapy consisting of esomeprazole and amoxicillin is superior to CAM-based triple therapy containing esomeprazole and amoxicillin as first-line eradication treatment against H. pylori.
[Mh] Termos MeSH primário: Claritromicina/uso terapêutico
Infecções por Helicobacter/tratamento farmacológico
Helicobacter pylori/efeitos dos fármacos
Metronidazol/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Amoxicilina/uso terapêutico
Antibacterianos
Quimioterapia Combinada
Esomeprazol/uso terapêutico
Feminino
Infecções por Helicobacter/microbiologia
Helicobacter pylori/isolamento & purificação
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 140QMO216E (Metronidazole); 804826J2HU (Amoxicillin); H1250JIK0A (Clarithromycin); N3PA6559FT (Esomeprazole)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171221
[Lr] Data última revisão:
171221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE
[do] DOI:10.1159/000481224


  5 / 8736 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29191308
[Au] Autor:Meng L; Li X; Wang X; Ma K; Liu G; Zhang J
[Ad] Endereço:School of Municipal and Environmental Engineering, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin 150090, China.
[Ti] Título:Amoxicillin effects on functional microbial community and spread of antibiotic resistance genes in amoxicillin manufacture wastewater treatment system.
[So] Source:J Environ Sci (China);61:110-117, 2017 Nov.
[Is] ISSN:1001-0742
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:This study aimed to reveal how amoxicillin (AMX) affected the microbial community and the spread mechanism of antibiotic resistance genes (ARGs) in the AMX manufacture wastewater treatment system. For this purpose, a 1.47 L expanded granular sludge bed (EGSB) reactor was designed and run for 241days treating artificial AMX manufacture wastewater. 454 pyrosequencing was applied to analyze functional microorganisms in the system. The antibiotic genes OXA- , OXA , OXA , TEM , CTX-M , class I integrons (intI1) and 16S rRNA genes were also examined in sludge samples. The results showed that the genera Ignavibacterium, Phocoenobacter, Spirochaeta, Aminobacterium and Cloacibacillus contributed to the degradation of different organic compounds (such as various sugars and amines). And the relative quantification of each ß-lactam resistance gene in the study was changed with the increasing of AMX concentration. Furthermore the vertical gene transfer was the main driver for the spread of ARGs rather than horizontal transfer pathways in the system.
[Mh] Termos MeSH primário: Amoxicilina/farmacologia
Antibacterianos/farmacologia
Bactérias/efeitos dos fármacos
Farmacorresistência Bacteriana/genética
Genes Bacterianos
Águas Residuais/microbiologia
[Mh] Termos MeSH secundário: Bactérias/genética
Eliminação de Resíduos Líquidos
Microbiologia da Água
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Waste Water); 804826J2HU (Amoxicillin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171207
[Lr] Data última revisão:
171207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE


  6 / 8736 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28457118
[Au] Autor:Antonelli D; Rozner E; Turgeman Y
[Ad] Endereço:Department of Cardiology, HaEmek Medical Center, Afula, Israel.
[Ti] Título:Kounis Syndrome: Acute ST segment Elevation Myocardial Infarction following Allergic Reaction to Amoxicillin.
[So] Source:Isr Med Assoc J;19(1):59-60, 2017 Jan.
[Is] ISSN:1565-1088
[Cp] País de publicação:Israel
[La] Idioma:eng
[Mh] Termos MeSH primário: Amoxicilina/efeitos adversos
Antibacterianos/efeitos adversos
Infarto do Miocárdio com Supradesnível do Segmento ST/induzido quimicamente
[Mh] Termos MeSH secundário: Hipersensibilidade a Drogas/complicações
Eletrocardiografia
Seres Humanos
Masculino
Meia-Idade
Síndrome
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 804826J2HU (Amoxicillin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  7 / 8736 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28863395
[Au] Autor:Theodoro LH; Lopes AB; Nuernberg MAA; Cláudio MM; Miessi DMJ; Alves MLF; Duque C; Mombelli A; Garcia VG
[Ad] Endereço:Department of Surgery and Integrated Clinic, Division of Periodontology, São Paulo State University (Unesp), School of Dentistry, Araçatuba, SP, Brazil. Electronic address: letheodoro@foa.unesp.br.
[Ti] Título:Comparison of repeated applications of aPDT with amoxicillin and metronidazole in the treatment of chronic periodontitis: A short-term study.
[So] Source:J Photochem Photobiol B;174:364-369, 2017 Sep.
[Is] ISSN:1873-2682
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:AIM: The aim of this study was to compare the clinical effects of Metronidazole (MTZ) combined with Amoxicillin (AMX) and repeated applications of antimicrobial photodynamic therapy (aPDT) as an adjuvant for the treatment of chronic periodontitis. METHODS: A double-blind controlled and randomized clinical trial was conducted in 34 patients. All of the patients were treated with scaling and root planing (SRP) and separated into 2 groups: the MTZ+AMX Group (n=17), who received SRP and the systemic use of MTZ (400mg 3×per day for 7days) and AMX (500mg 3×per day for 7days), and the aPDT Group (n=17), who received SRP and three aPDT applications at all sites with a probing depth≥5mm immediately, at 48 and 96h after scaling and placebo pills over the span of 7days. Clinical examinations were performed at baseline and 90days post-therapy. The clinical parameters of bleeding on probing (BOP), probing depth (PD), and clinical attachment level (CAL) were measured. The aPDT was conducted using methylene blue and a low-level laser (GaAlAs 660nm, 100mW, 48s, and 160J/cm ) in all sites with a probing depth≥5mm. A statistical analysis was also performed (α=5%). RESULTS: There was a significant improvement in CAL only in the intermediate pocket in the aPDT group compared to the MTZ+AMX group between baseline and 90days post-treatment (p=0.01). There was a reduction of both BOP and the percentage of residual pockets at 90days after treatment compared with baseline in both groups (p<0.05). CONCLUSION: Both proposed adjuvant therapies associated with conventional mechanical treatment in patients with chronic periodontitis were equally effective in terms of the gain of clinical insertion, control of inflammation and elimination of residual pockets.
[Mh] Termos MeSH primário: Amoxicilina/farmacologia
Antibacterianos/farmacologia
Periodontite Crônica/tratamento farmacológico
Metronidazol/farmacologia
Fotoquimioterapia/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Amoxicilina/uso terapêutico
Antibacterianos/uso terapêutico
Feminino
Seres Humanos
Masculino
Metronidazol/uso terapêutico
Meia-Idade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 140QMO216E (Metronidazole); 804826J2HU (Amoxicillin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170902
[St] Status:MEDLINE


  8 / 8736 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28806998
[Au] Autor:Kotaskova I; Nemec P; Vanerkova M; Malisova B; Tejkalova R; Orban M; Zampachova V; Freiberger T
[Ad] Endereço:Molecular and Genetics Laboratory, Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic.
[Ti] Título:First report of Sneathia sanguinegens together with Mycoplasma hominis in postpartum prosthetic valve infective endocarditis: a case report.
[So] Source:BMC Infect Dis;17(1):563, 2017 Aug 14.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The presence of more than one bacterial agent is relatively rare in infective endocarditis, although more common in prosthetic cases. Molecular diagnosis from a removed heart tissue is considered a quick and effective way to diagnose fastidious or intracellular agents. CASE PRESENTATION: Here we describe the case of postpartum polymicrobial prosthetic valve endocarditis in a young woman. Sneathia sanguinegens and Mycoplasma hominis were simultaneously detected from the heart valve sample using broad range 16S rRNA polymerase chain reaction (PCR) followed by sequencing while culture remained negative. Results were confirmed by independent PCR combined with denaturing gradient gel electrophoresis. Before the final agent identification, the highly non-compliant patient left from the hospital against medical advice on empirical intravenous treatment with aminopenicillins, clavulanate and gentamicin switched to oral amoxycillin and clavulanate. Four months after surgery, no signs of inflammation were present despite new regurgitation and valve leaflet flail was detected. However, after another 5 months the patient died from sepsis and recurrent infective endocarditis of unclarified etiology. CONCLUSIONS: Mycoplasma hominis is a rare causative agent of infective endocarditis. To the best of our knowledge, presented case is the first report of Sneathia sanguinegens detected in this condition. Molecular techniques were shown to be useful even in polymicrobial infective endocarditis samples.
[Mh] Termos MeSH primário: Endocardite Bacteriana/microbiologia
Infecções por Fusobacteriaceae/microbiologia
Leptotrichia/patogenicidade
Mycoplasma hominis/patogenicidade
Infecções Relacionadas à Prótese/microbiologia
[Mh] Termos MeSH secundário: Adulto
Amoxicilina/uso terapêutico
Antibacterianos/uso terapêutico
Endocardite Bacteriana/tratamento farmacológico
Feminino
Próteses Valvulares Cardíacas
Seres Humanos
Leptotrichia/genética
Leptotrichia/isolamento & purificação
Masculino
Infecções por Mycoplasma/tratamento farmacológico
Infecções por Mycoplasma/microbiologia
Mycoplasma hominis/genética
Período Pós-Parto
Gravidez
Infecções Relacionadas à Prótese/tratamento farmacológico
RNA Ribossômico 16S/genética
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (RNA, Ribosomal, 16S); 804826J2HU (Amoxicillin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170816
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2654-8


  9 / 8736 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28796053
[Au] Autor:Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
[Ad] Endereço:aState Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, bDepartment of Health Statistics, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
[Ti] Título:Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
[So] Source:Medicine (Baltimore);96(32):e7697, 2017 Aug.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Due to increasing antimicrobial resistance, a bismuth-based quadruple regimen has been recommended as an alternative first-line therapy for Helicobacter pylori (H pylori) eradication. However, different results are varied greatly and the availability of bismuth was limited in some countries. We assessed the efficacy and safety of 14-day berberine-containing quadruple therapy as an alternative regimen for H pylori eradication. METHODS: In a randomized, open-label, non-inferiority, phase IV trial between November 25, 2014, and October 15, 2015, 612 treatment-naive patients were randomly assigned to 14-day berberine-containing (n = 308) or 14-day bismuth-containing (n = 304) quadruple therapy. The primary outcomes were eradication rates determined by the C urea breath test (C-UBT) 28 days after the end of treatment. The secondary outcomes were adverse events and compliance. RESULTS: The baseline demographic data including age, gender, body mass index (BMI), general condition and severity score were not statistically different in both groups. The eradication rates in bismuth and berberine groups were 86.4% (266/308) and 90.1% (274/304) in intention-to-treat (ITT) analysis (P = .149), and 89.6% (266/297) and 91.3% (273/299) in per-protocol (PP) analysis (P = .470), respectively. No statistically significant difference was found in the overall incidence of adverse events between both groups (35.7% vs 28.6%, P = .060). CONCLUSIONS: Both regimens achieved the recommended efficacy for H pylori eradication. The berberine-containing quadruple regimen was not inferior to bismuth-containing quadruple regimen and can be recommended as an alternative regimen for H pylori eradication in the local region.
[Mh] Termos MeSH primário: Antiácidos/uso terapêutico
Antibacterianos/uso terapêutico
Berberina/uso terapêutico
Bismuto/uso terapêutico
Infecções por Helicobacter/tratamento farmacológico
Helicobacter pylori/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Amoxicilina/administração & dosagem
Antiácidos/administração & dosagem
Antiácidos/efeitos adversos
Antibacterianos/administração & dosagem
Antibacterianos/efeitos adversos
Berberina/administração & dosagem
Berberina/efeitos adversos
Bismuto/administração & dosagem
Bismuto/efeitos adversos
Índice de Massa Corporal
Testes Respiratórios
Claritromicina/administração & dosagem
Quimioterapia Combinada
Esomeprazol/administração & dosagem
Feminino
Seres Humanos
Masculino
Meia-Idade
Inibidores da Bomba de Prótons/administração & dosagem
Índice de Gravidade de Doença
Fatores Sexuais
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antacids); 0 (Anti-Bacterial Agents); 0 (Proton Pump Inhibitors); 0I8Y3P32UF (Berberine); 804826J2HU (Amoxicillin); H1250JIK0A (Clarithromycin); N3PA6559FT (Esomeprazole); U015TT5I8H (Bismuth)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170827
[Lr] Data última revisão:
170827
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007697


  10 / 8736 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28791844
[Au] Autor:Gosciniak G; Biernat MM; Binkowska A; Kus A; Iwanczak B
[Ad] Endereço:Department of Microbiology, Wroclaw Medical University, Poland.
[Ti] Título:Frequency of infection with Helicobacter pylori isolates of different antimicrobial profiles in children and adolescents: A preliminary study.
[So] Source:Adv Clin Exp Med;26(2):263-268, 2017 Mar-Apr.
[Is] ISSN:1899-5276
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Helicobacter pylori (H. pylori) infection can occur as a mixed infection caused by several strains of H. pylori. OBJECTIVES: The aim of the study was to determine the frequency of colonization of the gastric mucosa by strains of H. pylori with different susceptibility to antimicrobial agents. MATERIAL AND METHODS: The study was carried out on gastric biopsies taken from 54 previously untreated Polish children and adolescents. Of the 15 positive cultures, from each primary medium, 6 single H. pylori colonies were isolated, making a total of 90 isolates, and the susceptibility to metronidazole (MZ), amoxicillin (AC) and clarithromycin (CH) was determined by E-test method. The presence of the cagA gene and vacA alleles (s1, s2, m1, m2) was determined by PCR. RESULTS: Positive culture for H. pylori was noted in 15/54 (27.7%) of patients. All H. pylori isolates were susceptible to AC, 27.8% were resistant to MZ and 38.9% to CH. The results showed 7/15 (46.7%) of children were infected with H. pylori strains with antibiotic heteroresistance, resistant to CH (5/15, 33.3%) and to MZ (2/15, 13.3%). The cagA + vacA s1/m2 combination was predominant genotype among detected H. pylori strains. The isolates possessing different antimicrobial susceptibility profiles in the same patient were identified. CONCLUSIONS: Microbiological analyses confirmed the presence of isolates possessing different antimicrobial susceptibility profiles in 47% of examined children with H. pylori infection. Different antimicrobial susceptibility profiles of H. pylori isolates detected in the same patient may influence the success of eradication therapy.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Mucosa Gástrica/efeitos dos fármacos
Infecções por Helicobacter/tratamento farmacológico
Helicobacter pylori/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adolescente
Amoxicilina/uso terapêutico
Antígenos de Bactérias/genética
Proteínas de Bactérias/genética
Criança
Pré-Escolar
Claritromicina/uso terapêutico
Mucosa Gástrica/microbiologia
Mucosa Gástrica/patologia
Infecções por Helicobacter/epidemiologia
Infecções por Helicobacter/microbiologia
Helicobacter pylori/genética
Helicobacter pylori/fisiologia
Interações Hospedeiro-Patógeno/efeitos dos fármacos
Seres Humanos
Metronidazol/uso terapêutico
Testes de Sensibilidade Microbiana/métodos
Testes de Sensibilidade Microbiana/estatística & dados numéricos
Polônia/epidemiologia
Reação em Cadeia da Polimerase
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Antigens, Bacterial); 0 (Bacterial Proteins); 0 (VacA protein, Helicobacter pylori); 0 (cagA protein, Helicobacter pylori); 140QMO216E (Metronidazole); 804826J2HU (Amoxicillin); H1250JIK0A (Clarithromycin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170810
[St] Status:MEDLINE
[do] DOI:10.17219/acem/67716



página 1 de 874 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde